Common Contracts
5 similar Registration Rights Agreement contracts by ViewRay, Inc., OncoMed Pharmaceuticals Inc, Rockwell Medical, Inc.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 19th, 2018 • Rockwell Medical, Inc. • Electromedical & electrotherapeutic apparatus • New York
This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 17th day of October, 2018 by and between Rockwell Medical, Inc., a Michigan corporation (the “Company”), and The RBI Opportunities Fund, LLC, a Delaware limited liability company (the “Buyer”).
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 12th, 2018 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus • New York
This Amended and Restated Registration Rights Agreement (the “Agreement”) is made and entered into as of this 5th day of March, 2018 by and among ViewRay, Inc., a Delaware corporation (the “Company”), and Strong Influence Limited, a British Virgin Islands corporation (the “Holder”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 25th, 2017 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus • New York
This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 23rd day of October, 2017 by and among ViewRay, Inc., a Delaware corporation (the “Company”), and KVP Capital, LP (the “Holder”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 25th, 2017 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus • New York
This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 23rd day of October, 2017 by and among ViewRay, Inc., a Delaware corporation (the “Company”), and Strong Influence Limited, a British Virgin Islands corporation (the “Holder”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 3rd, 2013 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • California
This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 2, 2013, by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Celgene Corporation, a Delaware corporation (the “Investor”).
